TopClosure® tension‑relief system improves clinical outcomes of patients with breast cancer undergoing mastectomy

Exp Ther Med. 2022 Dec 14;25(1):70. doi: 10.3892/etm.2022.11769. eCollection 2023 Jan.

Abstract

The present randomized controlled study aimed to investigate the effects of TopClosure® tension-relief system (TRS) on patients with breast cancer undergoing mastectomy. A total of 402 female patients with breast cancer who came to the Renmin Hospital of Wuhan University between March 2014 and June 2018 were involved in the present study. All patients receiving mastectomy were randomly divided into the TRS group (n=201) and the control group (n=201). Serum levels of high-sensitivity C-reactive protein, TNF-α, IL-6 and procalcitonin were measured using ELISA. Vancouver Scar Scale was recorded at 2 weeks and 1-3 and 6 months following the operation. The 36-Item Health Survey Scales were performed for all patients at 1 month after surgery. The TRS reduced the incidence of flap necrosis, infection and the duration of hospital stay. In addition, the TRS was found to attenuate inflammation and improve scar outcomes as well as the quality of life. It was concluded that the TRS could significantly improve the clinical outcomes.

Keywords: breast cancer; clinical outcomes; inflammation; mastectomy; tension-relief system.

Grants and funding

Funding: No funding was received.